CCKAR
Cholecystokinin receptor type A
As of the edition of 20 October 2026, CCKAR (cholecystokinin receptor type A, UniProt P32238) has 5 drugs tested at it and 7 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P32238
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 14
- Disease areas
- Digestive system; Hormones; Nutrition and metabolism; Cancer
- Registered trials of its drugs
- 14
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 2 |
| Withdrawn from market | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Proglumide | Withdrawn from market | Phase 2 | none listed |
| Sincalide | Marketed | Phase 4 | none listed |
| CE-326597 | Went quiet | Phase 2 | none listed |
| Dexloxiglumide | Went quiet | Phase 3 | none listed |
| Ceruletide | Marketed | No phase stated | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Undetermined | 4 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Bracco Imaging | Route B |
| Viatris | Route A |
| Actavis | Route A |
The other 4 companies at CCKAR
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at CCKAR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.